Treatment of pervasive developmental disorders with redox-active therapeutics
AssigneeEdison Pharmaceuticals, Inc.
InventorsGuy M. MILLER, Viktoria KHEIFETS
Life of this patent
Estimating the term…
Abstract
Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
Claims31
A composition for reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD), in a patient in need of such treatment comprising one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or mixtures thereof,
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
- or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.
A medical food, a functional food, a food supplement, or a dietary supplement for reducing the symptoms associated with, or for treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD), in a patient in need of such treatment;
- comprising compositions of one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula Ia, Formula IIa, Formula IIIa, Formula IVa, Formula Va, Formula VIa, Formula Ib, Formula Ib-R, Formula Ib-S, Formula Ic, Formula Ic-RRR, Formula Ic-SRR, Formula Ic-RSR, Formula Ic-RRS, Formula Ic-SSR, Formula Ic-SRS, Formula Ic-RSS, Formula Ic-SSS, Formula IIIb, Formula IIIc, Formula IIIc-RRR, Formula IIIc-SRR, Formula IIIc-RSR, Formula IIIc-RRS, Formula IIIc-SSR, Formula IIIc-SRS, Formula IIIc-RSS, Formula IIIc-SSS, Formula Id, Formula IId, Formula IIId, or Formula IVd, and at least one of the group consisting of a physiologically or nutritionally acceptable carrier, adjuvant, excipient, buffer and diluent.
A method of reducing the symptoms associated with, or of treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment by administering a therapeutically or physiologically effective amount of one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, or mixtures thereof,
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
- or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.
Use of one or more compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, or mixtures thereof,
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen and CN;
- or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof;
- for reducing the symptoms associated with, or for treating or suppressing pervasive developmental disorders (PDDs) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment.
Dependencies are inferred from the claim text.